Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival

This data attempts, yet again, to suggest that Provenge is more effective when the cell counts are higher, and more of the cells have CD54 "helper" antigens on their surface. These data are similar to other misleading news releases about Provenge from Dendreon. This is a subset of patients from two trials, comprising about two-thirds of the total # of patients in the two Phase III trials, as...

It appears they finally made an attempt to infer causality from a previous result and determine what, if any, treatment effect was implied. I'm quite happy to see this type of analysis but would want to look at all the details, including the raw data if possible, before drawing too many conclusions. This can't hurt the regulatory efforts as long as it represents a robust conclusion...

esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor...